Table 4.
Clinical and endoscopic characteristics of the 13 patients where biopsy slides were reviewed again for the purpose of this study.
| Demographics age/race/sex |
Cancer | Immunotherapy | Symptoms | Endoscopy | Treatment | Overall Outcome |
|---|---|---|---|---|---|---|
| 60/W/M | Squamous cell lung | Nivolumab | Nausea/vomiting/abd pain | Erythematous mucosa/edema/ulcerations | PPI/prednisone 80 | Died |
| 74/W/F | Adenocarcinoma lung | Nivolumab | Nausea/pain/fatigue | Erythematous mucosa/edema/friability | PPI | Resolved |
| 74/B/M | Urothelial | Pembrolizumab | Abd pain/melena | Erosions/ulcerations | PPI/carafate/prednisone | Resolved |
| 76/W/F | Squamous cell lung | Nivolumab | Nausea/vomiting | Erythematous mucosa/edema/granularity | PPI/carafate | Immunotherapy cont. |
| 59/O/M | Adenocarcinoma lung | Pembrolizumab | Nausea/vomiting/abd pain | Erythematous mucosa/edema/friability | PPI/carafate/prednisone 80 | Unable to resume |
| 75/W/M | Adenocarcinoma lung | Nivolumab | Nausea, melena, anorexia | Erythematous mucosa/edema | PPI | Immunotherapy cont. |
| 65/W/F | Renal | Nivolumab | Abd pain/melena | Erythematous mucosa/erosions/ulcerations | PPI/carafate | Immunotherapy cont. |
| 50/W/M | Squamous cell lung | Durvalumab | Abd pain/nausea | Erythematous mucosa/edema/friability | PPI/prednisone 40 mg | Disease progression |
| 50/W/M | Melanoma | Nivolumab | Nausea, vomiting, abd pain, melena | Erythematous mucosa/erosions/edema | PPI/carafate | Resolved |
| 79/W/M | Melanoma | Ipilimumab/nivolumab | Nausea/vomiting/abd pain | Erythematous mucosa/friability | PPI/prednisone 50 mg | Resolved |
| 51/W/M | Non-Hodgkin’s lymphoma | Nivolumab | Bloating/abd pain | Erythematous mucosa/edema/erosions | PPI | Resolved |
| 43/W/F | Melanoma | Pembrolizumab | Abd pain/nausea | Erythematous mucosa/edema/friability | PPI/prednisone 70 mg | Resolved |
| 69/W/M | Mesothelioma | Ipilimumab/Nivolumab | Nausea/vomiting | Erosions/Ulcerations | PPI/prednisone 40 mg | Resolved |
Abbreviations: W, white; O, other; B, black; M, male; F, female; PPI, proton pump inhibitor.